Alpha Teknova (TKNO) earnings call transcripts

Management framed the quarter as broad-based growth supporting raised 2026 expectations, while emphasizing that biotech funding and commercial investments have not yet reached revenue.

Management framed the quarter as evidence of stabilizing demand, while keeping full-year guidance unchanged until order improvement proves durable.

Management framed 2025 as an execution and strategy inflection point, while emphasizing that faster growth depends on biotech recovery and clinical programs advancing.